deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT03907852

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer

Sponsor: Bristol-Myers Squibb

Conditions Cholangiocarcinoma Cholangiocarcinoma Recurrent High Grade Ovarian Serous Adenocarcinoma Mesothelioma Mesothelioma Peritoneum Mesothelioma, Malignant Mesothelioma; Pleura Mesotheliomas Pleural Non Small Cell Lung Cancer Non Small Cell Lung Cancer Metastatic Ovarian Cancer
Interventions Ipilimumab Nivolumab cyclophosphamide fludarabine gavo-cel
Updated 19 times since 2019 Last updated: Aug 20, 2025 Started: Apr 15, 2019 Primary completion: Nov 19, 2024 Completion: Nov 2, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Cholangiocarcinoma and Cholangiocarcinoma Recurrent, this trial is ongoing. The trial is conducted by Bristol-Myers Squibb and has accumulated 19 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Apr 2024 · 10 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2021 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • TCR2 Therapeutics
Data source: TCR2 Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations